Protocol: MHC class I and dengue hemorrhagic fever: a systematic review of HLA-A*24 and HLA-B*44

MHC class I and dengue hemorrhagic fever: a systematic review of HLA-A24 and HLA-B44

Protocols.io

Andrew Cook: Lake Erie College of Osteopathic Medicine - Bradenton ACook28563@med.lecom.edu

ORCID: https://orcid.org/0000-0001-6332-1993

Dylan Thibaut: Lake Erie College of Osteopathic Medicine - Bradenton, University of Central Florida

ORCID: https://orcid.org/0000-0002-8739-9688

Teresa Pettersen M.D..: Lake Erie College of Osteopathic Medicine - Bradenton

Dr. Teresa Pettersen is the PI of the research. Andrew Cook and Dylan Thibaut are first and second reviewers.

Amendments to the protocol will be provided if necessary.

No funding was acquired for this research.

The association of HLA alleles with dengue fever and dengue hemorrhagic fever is a topic of research interest. Dengue fever has been evaluated for associations with HLA alleles. In this study, we investigate the role of HLA class I alleles, HLA-A24 and HLA-B44 in a more severe form of the disease, dengue hemorrhagic fever.

This review investigates the role of HLA-A24 and HLA-B44 alleles in susceptibility or protection to dengue hemorrhagic fever compared to healthy control group. These results are compared to the role HLA-A24 and HLA-B44 contribute to protection or susceptibility to dengue fever.

Patients possessing HLA-A24 or HLA-B44 that were diagnosed with dengue hemorrhagic fever (DHF) or dengue fever (DF), including primary or secondary infection.

A systematic review will be performed. Studies from 2000 - 2022 will be included. Only studies published in English will be used. This study will be performed starting in May 2022.

HLA-A24 and HLA-B44 allele frequency/phenotype frequency data among those with dengue hemorrhagic fever will be compared to those with the given allele who are healthy. This will be repeated with dengue fever as well. This data will be inputted into Review Manager 5.4 to generate odds ratios from each study. These odds ratio will then be used to create forest plots. If a study contains multiple populations, these will be combined into one odds ratio. I² will be used in consideration for heterogeneity. MetaXL software can be used for any other tests necessary not covered by this program (for example: sensitivity testing) .

The Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system will be used in the evaluation of the strength of the body of evidence.

Google Scholar database will be used in the literature review.

The search terms will be used in Google Scholar, "HLA Dengue Fever", "HLA Dengue Hemorrhagic Fever". "HLA-A24 Dengue Hemorrhagic fever", "HLA-A24 Dengue fever", "HLA-B44 Dengue Hemorrhagic fever", "HLA-B44 Dengue fever". Limitations on study publication date from 2000-2022 will be applied.

A shared document will be used to manage records of sources and data collected. This data will be transferred to Review Manager 5.4 for further analysis.

Two independent reviewers selected studies in this research according to the following criteria.

Inclusion criteria: Patients possessing HLA-A24 or HLA-B44 that were diagnosed with dengue hemorrhagic fever (DHF) or dengue fever (DF), including primary or secondary infection. Studies using odds ratio or sufficient data available to calculate an odds ratio.

Exclusion criteria: Studies including patients diagnosed with dengue shock syndrome (DSS). Patients diagnosed according to the 2009 WHO guidelines of severe dengue and dengue. Studies in a foreign language, studies using animals as subjects, and studies not using odds ratio or studies with insufficient data available to calculate odds ratios.

Data will be extracted from studies independently.

HLA-A24 and HLA-B44 allele frequencies/phenotype frequencies of patients with dengue fever, dengue hemorrhagic fever, and healthy control populations will be gathered.

Outcomes: Determining odds of dengue hemorrhagic fever and dengue fever given presence of HLA-A24 or HLA-B44.

Risk bias assessment: The NIH quality assessment of case-control studies tool, and DOI plot will be used.

Current stage of research: preliminary planning and protocol creation.